Home

Vida Health Appoints Leading Industry Executives to Accelerate Growth in Cardiometabolic Care

via Business Wire

Alongside a recent capital raise, the company announced Chief Strategy Officer Jason Macaleer will partner with Chief Growth Officer Mike Rolla to meet growing demand for evidence-based obesity solutions.

Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity and related conditions, today announced the appointment of Jason Macaleer as Chief Strategy Officer and Mike Rolla as Chief Growth Officer. Seasoned healthcare leaders with a combined 40+ years of industry experience, Macaleer and Rolla will partner to help scale the company’s impact amid growing demand for evidence-based obesity and cardiometabolic solutions.

The announcement of Macaleer and Rolla’s appointments coincides with the completion of Vida Health’s recent capital raise led by existing investor General Atlantic, with participation from Ally Bridge, Canvas Prime, and existing shareholders, underscoring leading investors' support for the company’s strong market traction. In the last year, Vida has experienced significant growth, expanding its customer base by 70% and increasing revenue by greater than 90% year-to-date, driven by the company’s Clinical Obesity Management program. Combined with deepening partnerships with consultants, PBMs, and payers, this momentum underscores Vida’s emergence as the preferred partner for cardiometabolic care, particularly amid rising concerns about GLP-1 affordability and sustainability.

“Jason and Mike’s leadership and vision will be instrumental in our next phase of growth. Their complementary experience strengthens our ability to deliver sustainable solutions for obesity, diabetes, and related conditions,” said Joe Murad, CEO at Vida Health. “With our recent capital raise, which fully funds Vida to profitability, we are even better positioned to deliver on our mission and expand our impact, backed by the continued confidence of our investors.”

Macaleer joins Vida at a pivotal moment in the market, as employers and health plans navigate rising cardiometabolic risk and the evolving GLP-1 landscape. Macaleer brings deep expertise from strategic roles at Transcarent, Teladoc Health, and Livongo, where he scaled employer and health plan partnerships and advanced value-based care. He will support Vida’s mission of delivering partners and their members measurable, meaningful health outcomes, personalized care, and cost savings.

“It is a privilege to join the Vida team as we work to help address the obesity epidemic,” said Jason Macaleer. “I am energized by the opportunity to contribute to Vida’s continued growth and drive impactful results for our partners and their members.”

Rolla has a strong track record in commercializing innovative medical technologies and leading enterprise growth at companies like AliveCor, Teladoc/Livongo, and Becton Dickinson. His leadership in go-to-market strategy and complex enterprise sales will advance Vida’s expansion of responsible GLP-1 prescribing and comprehensive obesity care.

“It is rewarding to be part of Vida at such an exciting time of accelerated growth,” said Mike Rolla. “We are off to a strong start in 2025 and poised to continue our momentum with Jason and the rest of this impressive management team.”

Together, both executives offer a powerful blend of strategic vision, commercial acumen, and operational expertise as they work to strengthen employer and payer partnerships, optimize Rx integration, and accelerate Vida’s growth in the cardiometabolic market.

To learn more about how Vida helps health plans and employers improve the health of their members and employees, visit www.Vida.com.

About Vida Health

Vida Health is a virtual, personalized obesity care provider that helps patients manage obesity and related conditions like diabetes, high blood pressure, anxiety, and depression with evidence-based treatment. Vida’s team of obesity medicine-certified physicians, nurses, registered dietitians, expert coaches, and licensed therapists take a whole-person approach leading to clinically meaningful body weight loss in one year. Practicing responsible prescribing, Vida supports patients, employers, and health plans by prioritizing proven behavior change and lifestyle interventions before introducing medications, ensuring that only those who really need anti-obesity medications receive them — helping to control costs. For individuals with obesity, employers and health plans can save up to $550 in monthly prescription costs. Vida serves members in all 50 states and Washington D.C., offers services in both English and Spanish, and operates on a value-based pricing model, putting outcomes at the center of care. To learn more, visit www.Vida.com.

Contacts